Sulodexide may alleviate neointimal hyperplasia by inhibiting angiopoietin‑2 in an arteriovenous fistula model

Lei,Yan; Zheng,Zhihua; Wang,Ying; Liu,Yuyun; Liu,Rongjun; Xu,Qingdong; Yu,Xueqing

doi:10.3892/mmr.2013.1293

Sulodexide may alleviate neointimal hyperplasia by inhibiting angiopoietin‑2 in an arteriovenous fistula model

Authors:
- Yan Lei
- Zhihua Zheng
- Ying Wang
- Yuyun Liu
- Rongjun Liu
- Qingdong Xu
- Xueqing Yu
View Affiliations

Affiliations: Department of Nephrology, The First Affiliated Hospital, Sun Yat‑Sen University and Key Laboratory of Nephrology, Ministry of Health, Guangzhou 510080, P.R. China
Published online on: January 28, 2013 https://doi.org/10.3892/mmr.2013.1293
Pages: 831-835

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study was undertaken to confirm whether sulodexide aleviates neointimal hyperplasia by regulating angiopoietin/Tie in a rat femoral arteriovenous fistula (AVF) model. Sprague Dawley rats were divided into four groups: sham, model, treatment and treatment control. An arteriovenous shunt model was created in the model and treatment groups. Sulodexide was subcutaneously administered (10 mg/kg/day) 6 times per week for 8 weeks in the treatment and treatment control groups. Histology and immunofluorescence were analyzed and the protein expression of angiopoietin‑1, angiopoietin‑2, Tie‑2, p‑ERK and total‑ERK were tested by ELISA and/or western blotting after 8 weeks. HE staining revealed that sulodexide was able to partially alleviate intimal hyperplasia of remodeled veins in the AVF model. Additionally, sulodexide was able to decrease angiopoietin‑2 and Tie‑2 expression while increasing angiopoietin‑1 expression in AVF tissue. Sulodexide was also able to decrease ERK phosphorylation which was increased in the model. Serum levels of soluble Tie-2 (sTie‑2) were also significantly decreased by sulodexide compared with the model. Immunofluorescent analysis also confirmed that sulodexide was able to decrease angiopoietin‑2 expression, possibly partially by inhibiting endothelial cell proliferation. Sulodexide may alleviate venous intimal hyperplasia by regulating the angiopoietin/Tie system, which may play a significant role in assisting remodeled veins to cope with their new biomechanical environment, but whether the angiopoietin/Tie system is beneficial or not requires further study.

View Figures

View References

1	Manca O, Pisano GL, Carta P, et al: The management of hemodialysis arteriovenous fistulas in well functioning renal transplanted patients: many doubts, few certainties. J Vasc Access. 6:182–186. 2005.PubMed/NCBI
2	Lee T and Roy-Chaudhury P: Advances and new frontiers in the pathophysiology of venous neointimal hyperplasia and dialysis access stenosis. Adv Chronic Kidney Dis. 16:329–338. 2009. View Article : Google Scholar : PubMed/NCBI
3	Langer S, Heiss C, Paulus N, et al: Functional and structural response of arterialized femoral veins in a rodent AV fistula model. Nephrol Dial Transplant. 24:2201–2206. 2009. View Article : Google Scholar : PubMed/NCBI
4	Kokubo T, Ishikawa N, Uchida H, et al: CKD accelerates development of neointimal hyperplasia in arteriovenous fistulas. J Am Soc Nephrol. 20:1236–1245. 2009. View Article : Google Scholar : PubMed/NCBI
5	Langer S, Kokozidou M, Heiss C, et al: Chronic kidney disease aggravates arteriovenous fistula damage in rats. Kidney Int. 78:1312–1321. 2010. View Article : Google Scholar : PubMed/NCBI
6	Rodríguez-Pla A, Bosch-Gil JA, Rosselló-Urgell J, Huguet-Redecilla P, Stone JH and Vilardell-Tarres M: Metalloproteinase-2 and -9 in giant cell arteritis: involvement in vascular remodeling. Circulation. 112:264–269. 2005.PubMed/NCBI
7	Caplice NM, Wang S, Tracz M, et al: Neoangiogenesis and the presence of progenitor cells in the venous limb of an arteriovenous fistula in the rat. Am J Physiol Renal Physiol. 293:F470–F475. 2007. View Article : Google Scholar : PubMed/NCBI
8	Kanwar YS: Functional duality of progenitor cells influxing into arteriovenous fistula during its neoangiogenesis. Am J Physiol Renal Physiol. 293:F468–F469. 2007. View Article : Google Scholar : PubMed/NCBI
9	Maisonpierre PC, Suri C, Jones PF, et al: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 277:55–60. 1997. View Article : Google Scholar : PubMed/NCBI
10	David S, Kümpers P, Hellpap J, et al: Angiopoietin 2 and cardiovascular disease in dialysis and kidney transplantation. Am J Kidney Dis. 53:770–778. 2009. View Article : Google Scholar : PubMed/NCBI
11	Vandenbunder B: Angiopoietin-2, a new molecular actor involved in vascular tree morphogenesis. Bull Cancer. 84:1079–1080. 1997.(In French).
12	Augustin HG, Koh GY, Thurston G and Alitalo K: Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol. 10:165–177. 2009. View Article : Google Scholar : PubMed/NCBI
13	Chong AY, Caine GJ, Freestone B, Blann AD and Lip GY: Plasma angiopoietin-1, angiopoietin-2, and angiopoietin receptor tie-2 levels in congestive heart failure. J Am Coll Cardiol. 43:423–428. 2004. View Article : Google Scholar : PubMed/NCBI
14	Patel JV, Lim HS, Varughese GI, Hughes EA and Lip GY: Angiopoietin-2 levels as a biomarker of cardiovascular risk in patients with hypertension. Ann Med. 40:215–222. 2008. View Article : Google Scholar : PubMed/NCBI
15	Westra J, de Groot L, Plaxton SL, et al: Angiopoietin-2 is highly correlated with inflammation and disease activity in recent-onset rheumatoid arthritis and could be predictive for cardiovascular disease. Rheumatology (Oxford). 50:665–673. 2011. View Article : Google Scholar
16	Lauver DA, Booth EA, White AJ, Poradosu E and Lucchesi BR: Sulodexide attenuates myocardial ischemia/reperfusion injury and the deposition of C-reactive protein in areas of infarction without affecting hemostasis. J Pharmacol Exp Ther. 312:794–800. 2005. View Article : Google Scholar
17	Kim SB, Kim SH, Lee MS, Chang JW, Lee SK and Park JS: Effects of sulodexide on hemostatic factors, lipid profile, and inflammation in chronic peritoneal dialysis patients. Perit Dial Int. 27:456–460. 2007.PubMed/NCBI
18	Shustov SB: Controlled clinical trial on the efficacy and safety of oral sulodexide in patients with peripheral occlusive arterial disease. Curr Med Res Opin. 13:573–582. 1997. View Article : Google Scholar : PubMed/NCBI
19	Lunetta M and Salanitri T: Lowering of plasma viscosity by the oral administration of the glycosaminoglycan sulodexide in patients with peripheral vascular disease. J Int Med Res. 20:45–53. 1992.PubMed/NCBI
20	Rossini M, Naito T, Yang H, et al: Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy. Nephrol Dial Transplant. 25:1803–1810. 2010. View Article : Google Scholar : PubMed/NCBI
21	Lin T, Horsfield C and Robson MG: Arteriovenous fistula in the rat tail: a new model of hemodialysis access dysfunction. Kidney Int. 74:528–531. 2008. View Article : Google Scholar : PubMed/NCBI
22	Bongrazio M, Baumann C, Zakrzewicz A, Pries AR and Gaehtgens P: Evidence for modulation of genes involved in vascular adaptation by prolonged exposure of endothelial cells to shear stress. Cardiovasc Res. 47:384–393. 2000. View Article : Google Scholar : PubMed/NCBI
23	Dixit M, Bess E, Fisslthaler B, et al: Shear stress-induced activation of the AMP-activated protein kinase regulates FoxO1a and angiopoietin-2 in endothelial cells. Cardiovasc Res. 77:160–168. 2008. View Article : Google Scholar : PubMed/NCBI
24	Park HY, Kang S, Kim GY, et al: Inhibition of neointimal proliferation of rat carotid artery by sulodexide. J Korean Med Sci. 12:210–214. 1997. View Article : Google Scholar : PubMed/NCBI